Table 4

Participants with ≥1 solicited injection-site and systemic reactions 7 days after MCV4 or MPSV4 vaccinationa

ReactionResult by vaccination type
PSV exposedPSV naïve
MCV4 (n = 142)MPSV4 (n = 138)MCV4 (n = 158)
No. positive/total no.% (95% CI)No. positive/total no.% (95% CI)No. positive/total no.% (95% CI)
All injection-site reactions88/14262.0 (53.5–70.0)71/13851.4 (42.8–60.0)98/15862.0 (54.0–69.6)
    Pain85/14259.9 (51.3–68.0)66/13847.8 (39.3–56.5)95/15860.1 (52.0–67.8)
    Erythema39/14227.5 (20.3–35.6)34/13824.6 (17.7–32.7)42/15826.6 19.9–34.2)
    Swelling46/14232.4 (24.8–40.8)29/13821.0 (14.5–28.8)34/15821.5 (15.4–28.8)
Severe injection site reactions10/1427.0 (3.4–12.6)4/1382.9 (0.8–7.3)10/1586.3 (3.1–11.3)
Systemic reactions
    All87/14261.3 (52.7–69.3)86/13862.3 (53.7–70.4)90/15857.0 (48.9–64.8)
    Fever25/14217.6 (11.7–24.9)17/13812.3 (7.3–19.0)16/15810.1 (5.9–15.9)
    Headache66/14246.5 (38.1–55.0)64/13846.4 (37.9–55.1)60/15838.0 (30.4–46.0)
    Malaise61/14243.0 (34.7–51.5)55/13839.9 (31.6–48.5)61/15838.6 (31.0–46.7)
    Myalgia60/14242.3 (34.0–50.8)55/13839.9 (31.6–48.5)72/15845.6 (37.6–53.7)
Severe systemic reaction19/14213.4 (8.3–20.1)11/1388.0 (4.0–13.8)17/15810.8 (6.4–16.7)
  • a PSV exposed means participants who received meningococcal polysaccharide vaccine before study entry. PSV naïve means participants who did not receive meningococcal polysaccharide vaccine before study entry. MCV4 indicates participants who received quadrivalent meningococcal conjugate vaccine. MPSV4 indicates participants who received quadrivalent meningococcal polysaccharide vaccine.